Scholarlink

Introduction <p>A urine albumin–creatinine ratio (UACR) &gt; 700&#xa0;mg/g signifies severe kidney damage, and nephrology referral is recommended for intensified management. The impact of UACR ≥ 700&#xa0;mg/g on outcomes and the efficacy of kidney protective therapies in patients have not been thoroughly examined.</p> Methods <p>Using claims healthcare data from the USA, we identified prevalent patients with chronic kidney disease and a UACR measurement on 1 January 2022, and grouped them by UACR level. We also identified new users of sodium–glucose cotransporter&#xa0;2 inhibitors (SGLT2i) between 2021 and 2023. Outcomes included estimated glomerular filtration rate (eGFR) slopes and risks of adverse outcomes and mortality.</p> Results <p>Of the 46,626 patients with UACR ≥ 300&#xa0;mg/g, 23,998&#xa0;had UACR ≥ 700&#xa0;mg/g. In the UACR ≥ 700 and UACR 300 to &lt; 700&#xa0;mg/g groups, mean age was 72 and 74&#xa0;years, median eGFR was 42 and 50 mL/min/1.73&#xa0;m<sup>2</sup>, median UACR was 1376 and 437&#xa0;mg/g at baseline&#xa0;and&#xa0;eGFR slopes were − 5.5 and − 3.1 mL/min/1.73&#xa0;m<sup>2</sup> per year, respectively. Compared to the UACR &lt; 10&#xa0;mg/g group, adjusted hazard ratio of risk of cardiorenal hospitalizations was 5.83 (95%&#xa0;CI 5.55–6.12) and 3.53 (95%&#xa0;CI 3.34–3.73), atherosclerotic cardiovascular disease hospitalizations was 2.97 (95%&#xa0;CI 2.76–3.19) and 2.33 (95%&#xa0;CI 2.15–2.52), and all-cause death was 2.89 (95%&#xa0;CI 2.78–3.02) and 2.10 (95%&#xa0;CI 2.01–2.20) in the UACR ≥ 700 and UACR 300 to &lt; 700&#xa0;mg/g groups, respectively. Of the 5908 new users of SGLT2i with UACR ≥ 700&#xa0;mg/g, UACR and eGFR slope improved as expected (to 720&#xa0;mg/g and − 2.44&#xa0;mL/min/1.73&#xa0;m<sup>2</sup> per year, respectively).</p> Conclusions <p>A UACR ≥ 700&#xa0;mg/g identifies patients at high risk of accelerated kidney function decline and adverse outcomes. While emerging therapies such as SGLT2i had the expected benefits, the persistence of residual proteinuria/albuminuria and associated risks highlight an unmet need for optimized&#xa0;and new treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disease Progression, Clinical Outcomes and Treatment Challenges in Patients with Chronic Kidney Disease and High-Risk Proteinuria

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月15日

查看全文
  • Roberto Pecoits-Filho,
  • Johan Bodegård,
  • Phil Ambery,
  • You-Seon Nam,
  • Marcus Thuresson,
  • Maria K. Svensson

摘要

Introduction

A urine albumin–creatinine ratio (UACR) > 700 mg/g signifies severe kidney damage, and nephrology referral is recommended for intensified management. The impact of UACR ≥ 700 mg/g on outcomes and the efficacy of kidney protective therapies in patients have not been thoroughly examined.

Methods

Using claims healthcare data from the USA, we identified prevalent patients with chronic kidney disease and a UACR measurement on 1 January 2022, and grouped them by UACR level. We also identified new users of sodium–glucose cotransporter 2 inhibitors (SGLT2i) between 2021 and 2023. Outcomes included estimated glomerular filtration rate (eGFR) slopes and risks of adverse outcomes and mortality.

Results

Of the 46,626 patients with UACR ≥ 300 mg/g, 23,998 had UACR ≥ 700 mg/g. In the UACR ≥ 700 and UACR 300 to < 700 mg/g groups, mean age was 72 and 74 years, median eGFR was 42 and 50 mL/min/1.73 m2, median UACR was 1376 and 437 mg/g at baseline and eGFR slopes were − 5.5 and − 3.1 mL/min/1.73 m2 per year, respectively. Compared to the UACR < 10 mg/g group, adjusted hazard ratio of risk of cardiorenal hospitalizations was 5.83 (95% CI 5.55–6.12) and 3.53 (95% CI 3.34–3.73), atherosclerotic cardiovascular disease hospitalizations was 2.97 (95% CI 2.76–3.19) and 2.33 (95% CI 2.15–2.52), and all-cause death was 2.89 (95% CI 2.78–3.02) and 2.10 (95% CI 2.01–2.20) in the UACR ≥ 700 and UACR 300 to < 700 mg/g groups, respectively. Of the 5908 new users of SGLT2i with UACR ≥ 700 mg/g, UACR and eGFR slope improved as expected (to 720 mg/g and − 2.44 mL/min/1.73 m2 per year, respectively).

Conclusions

A UACR ≥ 700 mg/g identifies patients at high risk of accelerated kidney function decline and adverse outcomes. While emerging therapies such as SGLT2i had the expected benefits, the persistence of residual proteinuria/albuminuria and associated risks highlight an unmet need for optimized and new treatment strategies.